• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

磁共振左心室质量指数/纤维化:肥厚型心肌病中心室心律失常的长期预测指标——一项回顾性注册研究

Magnetic Resonance Left Ventricle Mass-Index/Fibrosis: Long-Term Predictors for Ventricular Arrhythmia in Hypertrophic Cardiomyopathy-A Retrospective Registry.

作者信息

Khan Habib Rehman, Rodwell Philip, Taha Ahmed Hasan, Goha Ahmed, Ahmed Mobeen, Thain Andrew Peter, Somarakis Konstantinos, Al-Atta Ayman, Erhayiem Bara, Uddin Akhlaque, Mathew Thomas

机构信息

Department of Cardiology, Nottingham University NHS Trust, Hucknall Road, Nottingham NG51PB, UK.

London Health Sciences Centre, University of Western Ontario, Windermere Road, London, ON N6G5A5, Canada.

出版信息

J Cardiovasc Dev Dis. 2023 Mar 13;10(3):120. doi: 10.3390/jcdd10030120.

DOI:10.3390/jcdd10030120
PMID:36975884
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10051998/
Abstract

: We aimed to study the long-term association of LV mass index (LV) and myocardial fibrosis with ventricular arrhythmia (VA) in a population of patients with confirmed hypertrophic cardiomyopathy (HCM) using cardiac magnetic resonance imaging (CMR). : We retrospectively analyzed the data in consecutive HCM patients confirmed on CMR referred to an HCM clinic between January 2008 and October 2018. Patients were followed up yearly following diagnosis. Baseline demographics, risk factors and clinical outcomes from cardiac monitoring and an implanted cardioverter defibrillator (ICD) were analyzed for association of LV and LV late gadolinium enhancement (LV) with VA. Patients were then allocated to one of two groups according to the presence of VA (Group A) or absence of VA (Group B) during the follow-up period. The transthoracic echocardiogram (TTE) and CMR parameters were compared between the two groups. : A total of 247 patients with confirmed HCM (age 56.2 ± 16.6, male = 71%) were studied over the follow-up period of 7 ± 3.3 years (95% CI = 6.6-7.4 years). LV derived from CMR was higher in Group A (91.1 ± 28.1 g/m vs. 78.8 ± 28.3 g/m, = 0.003) when compared to Group B. LV was higher in Group A (7.3 ± 6.3% vs. 4.7 ± 4.3%, = 0.001) when compared to Group B. Multivariable Cox regression analysis showed LV (hazard ratio (HR) = 1.02, 95% CI = 1.001-1.03, = 0.03) and LV (HR = 1.04, 95% CI = 1.001-1.08, = 0.04) to be independent predictors for VA. Receiver operative curves showed higher LV and LV with a cut-off of 85 g/m and 6%, respectively, to be associated with VA. : LV and LV are strongly associated with VA over long-term follow-up. LV requires more thorough studies to consider it as a risk stratification tool in patients with HCM.

摘要

我们旨在利用心脏磁共振成像(CMR),研究确诊肥厚型心肌病(HCM)患者群体中左心室质量指数(LV)和心肌纤维化与室性心律失常(VA)的长期关联。我们回顾性分析了2008年1月至2018年10月期间转诊至HCM诊所且经CMR确诊的连续性HCM患者的数据。患者确诊后每年进行随访。分析基线人口统计学、危险因素以及心脏监测和植入式心律转复除颤器(ICD)的临床结局,以探讨LV和左心室晚期钆增强(LV)与VA的关联。然后根据随访期间是否存在VA,将患者分为两组(A组:存在VA;B组:不存在VA)。比较两组的经胸超声心动图(TTE)和CMR参数。在7±3.3年(95%CI=6.6 - 7.4年)的随访期内,共研究了247例确诊HCM患者(年龄56.2±16.6岁,男性占71%)。与B组相比,A组源自CMR的LV更高(91.1±28.1g/m² 对78.8±28.3g/m²,P = 0.003)。与B组相比,A组的LV更高(7.3±6.3% 对4.7±4.3%,P = 0.001)。多变量Cox回归分析显示,LV(风险比(HR)=1.02,95%CI = 1.001 - 1.03,P = 0.03)和LV(HR = 1.04,95%CI = 1.001 - 1.08,P = 0.04)是VA的独立预测因素。受试者工作曲线显示,LV和LV分别以85g/m² 和6%为临界值时,与VA相关。LV和LV在长期随访中与VA密切相关。LV需要更深入的研究,以考虑将其作为HCM患者的风险分层工具。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3338/10051998/c7071c4419f7/jcdd-10-00120-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3338/10051998/4d7b035287f1/jcdd-10-00120-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3338/10051998/ae57334d3021/jcdd-10-00120-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3338/10051998/6ca47d1b5c0f/jcdd-10-00120-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3338/10051998/de58f11ead2c/jcdd-10-00120-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3338/10051998/31b9878e5429/jcdd-10-00120-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3338/10051998/10a5c1b8e120/jcdd-10-00120-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3338/10051998/cca3f7346815/jcdd-10-00120-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3338/10051998/7650176144ee/jcdd-10-00120-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3338/10051998/c7071c4419f7/jcdd-10-00120-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3338/10051998/4d7b035287f1/jcdd-10-00120-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3338/10051998/ae57334d3021/jcdd-10-00120-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3338/10051998/6ca47d1b5c0f/jcdd-10-00120-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3338/10051998/de58f11ead2c/jcdd-10-00120-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3338/10051998/31b9878e5429/jcdd-10-00120-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3338/10051998/10a5c1b8e120/jcdd-10-00120-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3338/10051998/cca3f7346815/jcdd-10-00120-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3338/10051998/7650176144ee/jcdd-10-00120-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3338/10051998/c7071c4419f7/jcdd-10-00120-g009.jpg

相似文献

1
Magnetic Resonance Left Ventricle Mass-Index/Fibrosis: Long-Term Predictors for Ventricular Arrhythmia in Hypertrophic Cardiomyopathy-A Retrospective Registry.磁共振左心室质量指数/纤维化:肥厚型心肌病中心室心律失常的长期预测指标——一项回顾性注册研究
J Cardiovasc Dev Dis. 2023 Mar 13;10(3):120. doi: 10.3390/jcdd10030120.
2
Prognostic significance of cardiac magnetic resonance-based markers in patients with hypertrophic cardiomyopathy.基于心脏磁共振的标志物对肥厚型心肌病患者的预后意义。
Int J Cardiovasc Imaging. 2021 Jun;37(6):2027-2036. doi: 10.1007/s10554-021-02165-8. Epub 2021 Feb 8.
3
Mean Scar Entropy by Late Gadolinium Enhancement Cardiac Magnetic Resonance Is Associated With Ventricular Arrhythmias Events in Hypertrophic Cardiomyopathy.延迟钆增强心脏磁共振成像测得的平均瘢痕熵与肥厚型心肌病的室性心律失常事件相关。
Front Cardiovasc Med. 2021 Nov 17;8:758635. doi: 10.3389/fcvm.2021.758635. eCollection 2021.
4
[The association between cardiac mr feature tracking strain and myocardial late gadolinium enhancement in patients with hypertrophic cardiomyopathy].肥厚型心肌病患者中心脏磁共振特征追踪应变与心肌延迟钆增强之间的关联
Kardiologiia. 2023 Feb 28;63(2):52-58. doi: 10.18087/cardio.2023.2.n2380.
5
Left ventricular structure and diastolic function by cardiac magnetic resonance imaging in hypertrophic cardiomyopathy.肥厚型心肌病中心脏磁共振成像评估左心室结构和舒张功能
Indian Heart J. 2018 Jan-Feb;70(1):75-81. doi: 10.1016/j.ihj.2016.12.021. Epub 2017 Jan 6.
6
Entropy of left ventricular late gadolinium enhancement and its prognostic value in hypertrophic cardiomyopathy a new CMR assessment method.肥厚型心肌病左心室晚期钆增强的熵及其预后价值:一种新的心脏磁共振评估方法
Int J Cardiol. 2023 Feb 15;373:134-141. doi: 10.1016/j.ijcard.2022.11.017. Epub 2022 Nov 14.
7
[Predicting value of 2014 European guidelines risk prediction model for sudden cardiac death (HCM Risk-SCD) in Chinese patients with hypertrophic cardiomyopathy].[2014年欧洲指南心脏性猝死风险预测模型(HCM Risk-SCD)对中国肥厚型心肌病患者的预测价值]
Zhonghua Xin Xue Guan Bing Za Zhi. 2017 Dec 24;45(12):1033-1038. doi: 10.3760/cma.j.issn.0253-3758.2017.12.006.
8
Prognostic value of cardiovascular magnetic resonance imaging for life-threatening arrhythmia detected by implantable cardioverter-defibrillator in Japanese patients with hypertrophic cardiomyopathy.心血管磁共振成像对日本肥厚型心肌病患者植入式心律转复除颤器检测到的危及生命心律失常的预后价值
Heart Vessels. 2018 Jan;33(1):49-57. doi: 10.1007/s00380-017-1030-3. Epub 2017 Aug 1.
9
Hypertensive heart disease versus hypertrophic cardiomyopathy: multi-parametric cardiovascular magnetic resonance discriminators when end-diastolic wall thickness ≥ 15 mm.高血压性心脏病与肥厚型心肌病:舒张末期室壁厚度≥15mm时的多参数心血管磁共振鉴别指标
Eur Radiol. 2017 Mar;27(3):1125-1135. doi: 10.1007/s00330-016-4468-2. Epub 2016 Jul 1.
10
Late Gadolinium Enhancement in Patients With Hypertrophic Cardiomyopathy and Preserved Systolic Function.肥厚型心肌病伴收缩功能保留患者的晚期钆增强。
J Am Coll Cardiol. 2018 Aug 21;72(8):857-870. doi: 10.1016/j.jacc.2018.05.060.

引用本文的文献

1
CMR-Derived Strain and Torsion Reveal Subclinical Dysfunction in Hypertrophic Cardiomyopathy: A Prospective Case-Control Study.心脏磁共振成像衍生的应变和扭转揭示肥厚型心肌病的亚临床功能障碍:一项前瞻性病例对照研究
Biomedicines. 2025 Aug 15;13(8):1986. doi: 10.3390/biomedicines13081986.
2
The Role of Nt-Pro-Bnp in Predicting Outcome in Pediatric Hypertrophic Cardiomyopathy.Nt-脑钠肽前体在预测小儿肥厚型心肌病预后中的作用
Pediatr Cardiol. 2024 Nov 24. doi: 10.1007/s00246-024-03702-7.

本文引用的文献

1
Ventricular arrhythmia and sudden cardiac death in hypertrophic cardiomyopathy: From bench to bedside.肥厚型心肌病中的室性心律失常与心源性猝死:从实验台到病床边
Front Cardiovasc Med. 2022 Aug 18;9:949294. doi: 10.3389/fcvm.2022.949294. eCollection 2022.
2
Recommendations for Multimodality Cardiovascular Imaging of Patients with Hypertrophic Cardiomyopathy: An Update from the American Society of Echocardiography, in Collaboration with the American Society of Nuclear Cardiology, the Society for Cardiovascular Magnetic Resonance, and the Society of Cardiovascular Computed Tomography.肥厚型心肌病患者多模态心血管成像建议:美国超声心动图学会的更新,与美国核医学学会、心血管磁共振学会和心血管计算机断层成像学会合作。
J Am Soc Echocardiogr. 2022 Jun;35(6):533-569. doi: 10.1016/j.echo.2022.03.012.
3
Arrhythmia Monitoring for Risk Stratification in Hypertrophic Cardiomyopathy.肥厚型心肌病风险分层的心律失常监测
CJC Open. 2022 Jan 7;4(4):406-415. doi: 10.1016/j.cjco.2022.01.001. eCollection 2022 Apr.
4
Copper chelation in patients with hypertrophic cardiomyopathy.铜螯合治疗肥厚型心肌病。
Open Heart. 2022 Feb;9(1). doi: 10.1136/openhrt-2021-001803.
5
Importance of newer cardiac magnetic resonance-based risk markers for sudden death prevention in hypertrophic cardiomyopathy: An international multicenter study.新型基于心脏磁共振成像的风险标志物在肥厚型心肌病猝死预防中的重要性:一项国际多中心研究
Heart Rhythm. 2022 May;19(5):782-789. doi: 10.1016/j.hrthm.2021.12.017. Epub 2021 Dec 18.
6
Hypertrophic Cardiomyopathy: From Phenotype and Pathogenesis to Treatment.肥厚型心肌病:从表型、发病机制到治疗
Front Cardiovasc Med. 2021 Oct 25;8:722340. doi: 10.3389/fcvm.2021.722340. eCollection 2021.
7
Risk factors of sudden cardiac death in hypertrophic cardiomyopathy.肥厚型心肌病患者发生心源性猝死的危险因素。
Curr Opin Cardiol. 2022 Jan 1;37(1):15-21. doi: 10.1097/HCO.0000000000000939.
8
Sudden cardiac death risk in hypertrophic cardiomyopathy: comparison between echocardiography and magnetic resonance imaging.肥厚型心肌病患者的心脏性猝死风险:超声心动图与磁共振成像的比较。
Sci Rep. 2021 Mar 30;11(1):7146. doi: 10.1038/s41598-021-86532-4.
9
Transthoracic echocardiography of hypertrophic cardiomyopathy in adults: a practical guideline from the British Society of Echocardiography.成人肥厚型心肌病的经胸超声心动图检查:英国超声心动图学会实用指南
Echo Res Pract. 2021 Jun 8;8(1):G61-G86. doi: 10.1530/ERP-20-0042.
10
2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.2020 年美国心脏病学会/美国心脏协会肥厚型心肌病诊断和治疗指南:执行摘要:美国心脏病学会/美国心脏协会临床实践指南联合委员会的报告。
Circulation. 2020 Dec 22;142(25):e533-e557. doi: 10.1161/CIR.0000000000000938. Epub 2020 Nov 20.